Apellis Pharmaceuticals Secures $275M Royalty Buy-Down Deal

Apellis Pharmaceuticals ( (APLS) ) just unveiled an announcement.

On July 1, 2025, Apellis Pharmaceuticals entered into a Royalty Buy-Down Agreement with Swedish Orphan Biovitrum AB, where Sobi will pay Apellis $275 million upfront and up to $25 million upon EMA approval of Aspaveli for certain conditions. In return, Sobi’s royalty obligations under a previous agreement will be reduced by 90%, with conditions tied to Aspaveli’s performance. This agreement, consented by the Company’s lenders, also extends certain prepayment premium periods under Apellis’s financing agreement by one year.

The most recent analyst rating on (APLS) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Apellis Pharmaceuticals stock, see the APLS Stock Forecast page.

Spark’s Take on APLS Stock

According to Spark, TipRanks’ AI Analyst, APLS is a Neutral.

The overall stock score for Apellis Pharmaceuticals is driven primarily by its financial performance challenges, reflected in persistent net losses and negative cash flows. Technical analysis indicates weak market momentum, while valuation metrics suggest the stock may be overvalued. Despite some positive developments in the earnings call, such as FDA Priority Review for EMPAVELI, the revenue shortfalls and operational challenges weigh heavily on the score.

To see Spark’s full report on APLS stock, click here.

More about Apellis Pharmaceuticals

Apellis Pharmaceuticals is a biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases. Its primary products include treatments targeting the complement system, with a market focus on rare diseases.

Average Trading Volume: 2,569,906

Technical Sentiment Signal: Sell

Current Market Cap: $2.19B

For an in-depth examination of APLS stock, go to TipRanks’ Overview page.